Clinical Trials on Unclassified Renal Cell Carcinoma

Total 12231 results

Bradley A. McGregor, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Metastatic Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Unclassified Renal Cell Carcinoma | Stage II Renal Cell Cancer AJCC v7

United States, Canada, Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
Jonsson Comprehensive Cancer Center
BeiGene; Driven To Cure

Withdrawn

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Kidney Medullary Carcinoma | Advanced Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditions

United States
Australian and New Zealand Urogenital and Prostate...

Recruiting

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell Carcinoma

Australia
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
Peloton Therapeutics, Inc.

Active, not recruiting

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Kidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, Recurrent

United States
Amgen

Completed

AMG 172 First in Human Study in Patients With Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell Adenocarcinoma

France, United States, Germany
National Cancer Institute (NCI)

Completed

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)

Terminated

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell Carcinoma

United States
Celldex Therapeutics

Terminated

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Kidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell Carcinoma

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal Cancer

United States
NiKang Therapeutics, Inc.
Pfizer

Recruiting

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Neoplasms | Kidney Cancer | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Kidney Diseases | Urologic Diseases | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recurrent... and other conditions

United States
Association Pour La Recherche des Thérapeutiques...

Completed

Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus (NEORAD)

Clear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal Carcinoma

France
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc) | Papillary Renal Cell Carcinoma (Prcc)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Advanced Renal Cell Carcinoma | Unresectable Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Adult Solid Neoplasm

United States
Australian and New Zealand Urogenital and Prostate...
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)

Renal Cell Carcinoma, Clear Cell | Metastatic Kidney Cancer

Australia
Agensys, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Carcinoma, Renal Cell | Renal Cell Carcinoma of Papillary Histology | Renal Cell Carcinoma With Clear Cell Histology | Renal Cell Carcinoma With Non-Clear Cell Histology

United States, Canada
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
Mayo Clinic

Recruiting

Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Clear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal Tumor

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
University of Washington
Merck Sharp & Dohme LLC; Prometheus Laboratories

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Completed

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

Canada
Novartis Pharmaceuticals

Completed

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (MACS0460)

Adenocarcinoma | Carcinoma | Renal Cell | Non Clear Cell Renal Carcinoma | Papillary Cell Renal Carcinoma

France, Italy, Belgium, Germany, Spain, Poland
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Guru Sonpavde
Pfizer; Hoosier Cancer Research Network

Withdrawn

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Kidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Cancer | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
City of Hope Medical Center

Completed

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Jonsson Comprehensive Cancer Center
Kite, A Gilead Company

Completed

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Stanford University
National Cancer Institute (NCI)

Terminated

Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Terminated

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Clear Cell Renal Cell Carcinoma | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Millennium Pharmaceuticals, Inc.

Completed

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Clear-cell Metastatic Renal Cell Carcinoma

Spain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
Rennes University Hospital

Completed

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma (RTKI)

Metastatic Clear Cell Renal Cell Carcinoma

France
Radboud University Medical Center

Completed

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

Netherlands

Clinical Trials on Unclassified Renal Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations